Fig. 1 · Structure

Documents & Downloads

SJB2-043

Cat. No. A15238 CAS 63388-44-3

USP1 Inhibitor

SJB2-043 is one of analogs/derivatives of C527, which is a novel and potent USP1 (ubiquitin-specific protease 1) inhibitor.

In Stock

Publications for SJB2-043

1 publication citing this product

  1. Kevin Bohm, .et al. , Arch Pharm (Weinheim), 2023, Jul;356(7):e2200661 PMID: 37196427

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

SJB2-043 reduced native USP1 activity-probe labeling in extracts from treated K562 cells. This is consistent with reduced USP1 activity but can also reflect changes in protein abundance; it does not establish exclusive USP1 selectivity or a binding site. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

SJB2-043 Research Summary

This section summarizes 3 in vitro studies of SJB2-043 from 2 published references. In vitro models include native USP1 in extracts of human K562 leukemia cells; human K562 leukemia cells.

SJB2-043 In Vitro Studies

In K562 leukemia cells, 24-hour SJB2-043 exposure reduced survival and increased apoptosis. The authors reported a survival EC50 of approximately 1.07 μM ± 0.08, with the uncertainty described as 95% confidence limits. [1]

In A549 lung cancer cells, SJB2-043 decreased the CCK-8 viability readout after 24 hours across the unambiguous 0.625–10 μM test groups. These cellular observations do not by themselves establish a USP1-specific mechanism. [2]

Native USP1 activity-probe competition after K562 treatment

Biochemical assay · Native USP1 in extracts of human K562 leukemia cells [1]

SJB2-043 treatment reduced formation of the USP1–Ub-VS adduct relative to DMSO. Ub-aldehyde served as a nonspecific DUB-inhibition control. Anti-HA signals show that effects were not confined to a demonstrated single DUB.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
USP1 labeling with HA-Ub-VSqualitative inhibition Reduced USP1–Ub-VS adduct formation[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
24 h cell treatment; 45 min probe incubation
Method
Cell pretreatment followed by lysate activity-probe labeling with 0.5 μM Ub-VS
Vehicle
DMSO; final fraction not specified
Reported limits
Replicate count and quantitative labeling inhibition are not stated in the adopted caption. This lysate endpoint does not establish selective binding or a binding site.
Methods and source locations

Compound reported in the paper: SJB2-043

Applies to the reported SJB2-043 research compound; supplier or Adooq lot equivalence is not established.

Figure 1H–I and caption; Results: USP1 inhibitor SJB2-043 inhibits the enzyme activity of native USP1; In Vitro Deubiquitination Assays

USP1 labeling with HA-Ub-VS: Anti-USP1 and anti-HA immunoblotting; untreated extract with and without probe and Ub-aldehyde control — Figure 1H–I and caption; Results: USP1 inhibitor SJB2-043 inhibits the enzyme activity of native USP1; In Vitro Deubiquitination Assays

K562 survival and apoptosis concentration response

Cell-based study · Human K562 leukemia cells [1]

After 24 h, SJB2-043 reduced viable K562 cell numbers and increased apoptosis with increasing concentration compared with DMSO. The reported survival EC50 is distinct from enzyme IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
K562 survivalEC50 approximately 1.07 μM ± 0.08 (95% Confidence Limits)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration response through 10 μM (Figure 2D–E); EC50 is an endpoint, not a fixed treatment dose
Exposure duration
24 h
Method
Cells grown in triplicate with SJB2-043 or DMSO
Vehicle
DMSO; final fraction not specified
Reported limits
Caption reports triplicate; biological versus technical replication is not specified. No exact apoptosis percentages transcribed from graph.
Methods and source locations

Compound reported in the paper: SJB2-043

Applies to the reported SJB2-043 research compound; supplier or Adooq lot equivalence is not established.

Figure 2D–E and caption; Results: USP1 inhibitors are cytotoxic to leukemic cells; Cells and drug treatments

K562 survival: Viable-cell assay; shared methods list Trypan blue, CellTiter-Glo or MTT without assigning a specific one to panel D. Apoptosis assessed by Annexin V/7AAD flow cytometry. — Figure 2D–E and caption; Results: USP1 inhibitors are cytotoxic to leukemic cells; Cells and drug treatments

A549 cell viability after 24-hour exposure

Cell-based study · Human A549 lung cancer cells [2]

SJB2-043 reduced the CCK-8 viability readout with increasing concentration. Analysis is restricted to the unambiguous 0.625, 2.5 and 10 μM groups versus the zero-compound control. Figure caption reports mean ± SD, n = 9; the independence of those replicates is unspecified.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
A549 CCK-8 viability relative to controlqualitative concentration response Decreased viability across the common 0.625, 2.5 and 10 μM groups[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.625, 2.5 and 10 μM; 0 μM control
Exposure duration
24 h exposure; 2 h CCK-8 incubation
Method
CCK-8 viability assay
Vehicle
Not specified in the read methods
Reported limits
Methods list 0.39 μM whereas Figure 3A labels 0.039 μM; that low-dose group is excluded. No IC50 is given for this adopted endpoint. This viability assay does not prove USP1-specific causality. Colony formation in panel B is excluded because its dose labels conflict with Methods 2.6.
Methods and source locations

Compound reported in the paper: SJB2-043

Named SJB2-043 in A549 cells; no Adooq material validation.

Methods 2.1, 2.2, 2.5 and 2.11; Results 3.3; Figure 3A and caption

A549 CCK-8 viability relative to control: CCK-8 absorbance at 450 nm after 24 h treatment and 2 h reagent incubation; Figure 3A reports mean ± SD, n = 9, one-way ANOVA — Methods 2.1, 2.2, 2.5 and 2.11; Results 3.3; Figure 3A and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 63388-44-3
Applications USP1 Inhibitor
Formula C17H9NO3
Molecular Weight 275.26
SMILES
C1=CC=C(C=C1)C2=NC3=C(O2)C(=O)C4=CC=CC=C4C3=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 1 mg/mL (3.63 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SJB2-043 Research References

  1. [1] Mistry H, Hsieh G, Buhrlage SJ, et al. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells Molecular cancer therapeutics (2013). PMID: 24130053 DOI: 10.1158/1535-7163.mct-13-0103-t Source material
  2. [2] Wu L, Yu M, Liang H, et al. SJB2-043, a USP1 Inhibitor, Suppresses A549 Cell Proliferation, Migration, and EMT via Modulation of PI3K/AKT/mTOR, MAPK, and Wnt Signaling Pathways Current issues in molecular biology (2025). PMID: 40136409 DOI: 10.3390/cimb47030155 Source material

Publications

1 publication citing this product

  1. Kevin Bohm, .et al. , Arch Pharm (Weinheim), 2023, Jul;356(7):e2200661 PMID: 37196427

Added to your cart

View Cart Checkout
Loading...